Drs. Prati, Hull and Associates was founded in June 1971. At the time, there were two physicians and less than 10 administrative support members. The subspecialty of nephrology was new.
Dr. Alan R. Hull became elected as the first president of Drs. Prati, Hull and Associates.
Dallas Kidney Disease Center was opened by Drs. Prati, Hull and Associates. Dallas Kidney Disease Center was the second dialysis center to open in Dallas, TX. At the time, it was the largest dialysis center in the world, with 53 dialysis stations.
Drs. Hull, White and Paul Peters, Sr., established a nonprofit organ recovery organization named Southwest Organ Bank. With support from The University of Texas Southwestern Medical Center, the organization increased the availability of kidneys for transplant. Dr. Martin White was the founding President and remained in that office until the year 2000. (Source: BUMC Group Practice Article – F. David Winter, Jr., MD)
Drs. Prati, Hull and Associates changed its name to Dallas Nephrology Associates.
Dallas Nephrology Associates’ physicians led by Dr. Pedro Vergne-Marini assisted in the development of the Methodist Medical Center transplant program, which performed their first kidney transplant in 1981.
Dallas Nephrology Associates opened Dallas Transplant Institute. Dallas Transplant Institute provides medical care for post-kidney and kidney/pancreas transplant patients and coordinates the medical evaluation for patients with CKD who have applied for kidney transplantation.
Dr. Thomas Parker, III, helped to lead the National Cooperative Dialysis Study (NCDS). NCDS was the first randomized and controlled trial that investigated the impact of dialysis doses on patients’ outcomes. Prior to this study, there was no standardized target BUN or HD session duration among patients with ESRD. The NCDS provided the first evidence that monitoring small solute clearance was an effective means of quantification of dialysis dose.
Dr. Martin G. White was elected as president of Dallas Nephrology Associates.
Dallas Nephrology Associates assisted in the development of the Baylor Transplant Program.
Dallas Nephrology Associates began a multicenter study to assess the impact of increasing the delivered quantity of dialysis on mortality in subsequent years. Dialysis dose was measured by urea kinetic modeling. Kt/V, reflecting the fractional volume of body water clearance of urea during a dialysis treatment.
By 1992, Dallas Nephrology Associates and National Medical Care had standardized mortality ratios of 0.77 and 0.74, respectively, compared with the US dialysis population, indicating almost 30% fewer observed deaths than expected resulted from the increase in Kt/V.
Dr. Pedro Vergne-Marini was elected as President of Dallas Nephrology Associates. Dr. Vergne was instrumental in creating new relationships with many dialysis partners.
Medical City Dallas Hospital expanded their transplant program to include kidney transplants. Our physicians included Medical Directors of the transplant program.
Dr. Ruben Velez was elected as President of Dallas Nephrology Associates. Dr. Velez served as President for 16 years. Under his leadership, DNA grew tremendously throughout the metroplex.
Baylor All Saints Medical Center in Fort Worth opened a transplant program with Dallas Nephrology Associates physicians providing both pre-transplant evaluation and post-transplant care.
Dr. Thomas Parker chaired the CKD Initiative workshop held by the Chronic Kidney Disease Initiative (CKDI) in Washington, DC. The CKDI was implemented at the request of the Council of American Kidney Societies to formulate a plan of action to solve many of the perceived problems associated with identifying, caring for, and attaining the best outcomes for patients with chronic kidney disease.
DNA Plano Vascular Center was opened. DNA Plano Vascular Center provides advanced, effective vascular-access management care to patients with dialysis access.
The 80th Texas Legislature passed House Bill 1373 in 2007. The bill established the Chronic Kidney Disease Task Force (Task Force). This task force was directed to develop a plan to educate health care professionals about the advantages and methods of early screening, diagnosis, and the treatment of CKD and its complications including early renal replacement therapy.
DNA Dallas Vascular Center was acquired from U.S. Vascular Access Services. The DNA Dallas Vascular Center provides advanced, effective vascular-access management care to patients with dialysis access. Our medical teams at both of our Vascular Centers include both Interventional Radiologists and Interventional Nephrologist, as well as surgical support staff.
Renal Disease Research Institute was formed. Renal Disease Research Institute is an affiliate of Dallas Nephrology Associates and its mission is to offer individuals the opportunity to participate in clinical research by managing scientifically feasible and ethical clinical trials.
Dr. Alexander Liang was elected as President of Dallas Nephrology Associates.
DNA was one of thirteen original pioneer members of ESCO, an ESRD specialty ACO.
Dr. Steven Hays becomes President of the Texas Chapter of the American College of Physicians.
Dallas Nephrology Associates’ Vascular Center is the first in Texas to create non-surgical dialysis fistulas using two FDA-approved systems.
Dallas Nephrology Associates’ Dr. Roberto Collazo-Maldonado was appointed to Chronic Kidney Disease Task Force by Governor Greg Abbott. Approved by the Texas Legislature in June 2019, Texas House Bill 1225, named The Glenda Dawson Act, re-established the Chronic Kidney Disease Task Force to coordinate the implementation of the state’s plan to increase prevention, early screening, diagnosis, and management of chronic kidney disease (CKD).
Dr. Neghae Mawla, Interventional Nephrologist, successfully completed the 100th EndoAVF procedure at the DNA Vascular Center in Plano. The EndoAVF procedure provided a minimally invasive approach to fistulas and changed the way doctors prepared their patients for hemodialysis.
Dr. Archana Rao was elected to the Dallas County Medical Society Board of Directors.
For over 50 years, Dallas Nephrology Associates has been caring for patients with kidney disease, hypertension, transplants, and complicated electrolyte disorders. While much has changed over the years, one thing remains constant—our pledge to provide our patients with expert, personalized care using the most advanced treatments and state-of-the-art technologies. Equally important is our excellent team of 100-plus physicians, 12-plus advanced practice providers, and more than 295 support staff who care for our patients with compassion and dedication.